New Zealand markets closed

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.2900-0.0600 (-1.79%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 551.26M
Enterprise value 341.51M
Trailing P/E 2.83
Forward P/E 177.52
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)1.07k
Price/book (mrq)5.40
Enterprise value/revenue 31.26k
Enterprise value/EBITDA 7-1.70

Trading information

Stock price history

Beta (5Y monthly) 0.14
52-week change 3-55.18%
S&P500 52-week change 333.64%
52-week high 38.4700
52-week low 33.1400
50-day moving average 33.6800
200-day moving average 35.1895

Share statistics

Avg vol (3-month) 365.36k
Avg vol (10-day) 322.05k
Shares outstanding 514.69M
Implied shares outstanding 6N/A
Float 88.66M
% held by insiders 132.66%
% held by institutions 111.41%
Shares short (29 Sep 2021) 466.2k
Short ratio (29 Sep 2021) 41.82
Short % of float (29 Sep 2021) 40.50%
Short % of shares outstanding (29 Sep 2021) 40.45%
Shares short (prior month 30 Aug 2021) 459.09k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-74,993.94%

Management effectiveness

Return on assets (ttm)-104.86%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)33k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-96.70%
Gross profit (ttm)-15.96M
EBITDA -24.39M
Net income avi to common (ttm)-24.98M
Diluted EPS (ttm)-2.4790
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.59M
Total cash per share (mrq)0.3
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)0.38
Book value per share (mrq)-1.20

Cash flow statement

Operating cash flow (ttm)-21.29M
Levered free cash flow (ttm)-9.5M